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Summary 
Background: High-density lipoproteins (HDL) have athero-
protective biological properties: antioxidative, anti-apoptot-
ic, anti-inflammatory, and they have the efflux capacity of
cellular cholesterol. Plasma mRNA analysis can be used to
investigate statin pleiotropy in vivo as a new analytical tool
for non-invasive assessment of gene expression in vascular
beds. The aim of this study was to assess the pleiotropic
effects of atorvastatin in stable angina patients with high-
risk values (group A) as compared with patients who had
borderline and desirable HDL-cholesterol (HDL-C) values
(group B). 
Methods: The atorvastatin therapy (20 mg/day) was given
to forty-three patients with stable angina for 10 weeks. We
investigated three statin pleiotropy-targeted genes: inter-
cellular adhesion molecule-1, chemokine (C-C motif) lig-
and 2 and cathepsin S and assessed by gel electrophoresis
gradient the effects of atorvastatin on HDL size and sub-
classes.
Kratak sadr`aj
Uvod: Lipoproteini velike gustine (HDL) imaju ateroprotek-
tivne biolo{ke osobine: antioksidativne, antiapoptoti~ke, anti -
inflamatorne kao i kapacitet da izvla~e holesterol iz }elija.
Analiza plazmatske mRNA mo`e da se koristi za ispitivanje
plejotropnih efekata statina in vivo kao novo analiti~ko sred-
stvo za neinvazivnu procenu ekspresije gena u zidu krvnog
suda. Cilj ove studije je bio da se procene plejotropni efekti
atorvastatina kod pacijenata sa stabilnom anginom sa
visoko rizi~nim vrednostima (grupa A) u odnosu na pacijente
sa grani~nim i po`eljnim vrednostima HDL holesterola (HDL-
C) (grupa B). 
Metode: ^etrdeset tri pacijenta sa stabilnom anginom su pri-
mala terapiju atorvastatinom (20 mg/dan) 10 nedelja. Mi
smo ispitivali tri gena zna~ajna za plejotropno delovanje stati-
na: intracelularni adhezioni molekul-1, hemokin (C-C motiv)
ligand 2 i katepsin S i procenjivali smo efekte atorvastatina
na veli~inu i raspodelu HDL subfrakcija pomo}u elektro-
foreze na poliakrilamidnom gradijent gelu.
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Introduction
High-density lipoproteins (HDL) have atheropro-
tective biological properties: antioxidative, antiapop-
totic, antiinflammatory, and they have the efflux ca -
pacity of cellular cholesterol (1). These plasma HDL
particles have heterogeneous physicochemical proper-
ties, metabolism, and biological activity (1). HDL is the
next target in reducing cardiovascular risk in statin-
treated high-risk patients, as evidenced from epidemi-
ological data, the data based on animal studies and
clinical trials (2). Prospective studies have shown that
coronary heart disease (CHD) risk was increased by
3% in women and by 2% in men per decrement of 1
mmol/L in HDL-C (3). Therapeutic normalisation of
attenuated antiatherogenic HDL function is the target
of modern pharmacological approaches to HDL rais-
ing (1). Common cardiovascular prevention strategies
emphasise therapeutic reductions in low-density
lipoprotein cholesterol (LDL-C) (4), however, attention
is being focused on HDL cholesterol as a secondary
prevention target to address the risk of residual cardio-
vascular disease (CVD) (5).
Statins, the inhibitors of 3-hydroxy-3-methylglu-
taryl coenzyme A (HMG-CoA) reductase, are drugs
that effectively reduce LDL-C levels. The studies indi-
cate that the overall benefits observed with statins can
be mediated through cholesterol-independent
effects, the so-called pleiotropic effects (6). Plasma
mRNA analysis, as a new research tool for the non in -
vasive follow-up of gene expression in vascular walls,
can be used to investigate statin pleiotropy in vivo (7). 
Monocyte chemoattractant protein-1 (MCP-1) is
the major chemokine responsible for attracting
monocytes to sites of active inflammation, including
the formation of atheromatous plaque (8). The
ICAM-1 is considered a major factor when circulating
monocytes adhere to the endothelium and then
transmigrate into the intima (9). Macrophages,
smooth muscle cells, and endothelial cells synthesise
cathepsin S (CTSS) (10). When released extracellular-
ly, CTSS exerts collagenolytic and elastolytic activities
which have as effects: elastic lamina degradation,
plaque rupture, and necrotic core formation (11, 12). 
In this study, we assessed the effects of atorvas-
tatin on HDL size and subclasses. In addition, the aim
of this study was to assess the pleiotropic effects of
atorvastatin (20 mg/day, for 10 weeks) on markers of
inflammation, oxidative stress and destabilisation of
atherosclerotic plaque in stable angina patients with
high-risk values, as compared with patients who had
borderline and desirable HDL-C values. We investigat-
ed three statin pleiotropy-targeted genes: intercellular
adhesion molecule-1 (ICAM1), chemokine (C-C
motif) ligand 2 (CCL2) and cathepsin S (CTSS).
Materials and Methods
Subjects and blood sampling
The atorvastatin therapy (20 mg/day) was given
to forty-three patients with stable angina for 10
weeks. Stable angina was diagnosed by clinical
assessment, electrocardiogram evaluation and labo-
ratory findings (13). Criteria for the inclusion of
patients were a stable angina diagnosis and statin free
treatment for at least one year. Criteria for the exclu-
sion of patients were (by detailed history and clinical
examination): inflammatory, endocrine, thyroid, liver,
neoplastic and renal diseases (serum creatinine con -
centration values ≥ 120 mmol/L). Likewise, patients
with hemolysed samples were excluded from the
study.
The patients with stable angina from the Health
Centre Laktasi (Bosnia and Herzegovina) were con-
secutively enrolled in our study. Blood was collected
from the subjects prior to therapy and 10 weeks later.
The study was approved by the National Ethics Com -
mittee. All participating subjects gave their written
consent. The procedure for collecting cell-free plas-
ma, a detailed description, has been published else-
where (7). 
mRNA quantification in plasma 
RNA was isolated from 3 mL of plasma using
QIAvac 24 Plus (Qiagen) and QIAamp Circulating
Results: In group A, after therapy, HDL-C concentration
was significantly increased but not in group B.  Atorvastatin
lowered plasma chemokine (C-C motif) ligand 2 and inter-
cellular adhesion molecule-1 mRNA levels in both groups,
but did not change the plasma cathepsin S mRNA levels.
In group A only, baseline total bilirubin showed negative
cor relations with the genes of cathepsin S (r=–0.506;
p=0.023) and significantly increased after therapy. 
Conclusions: HDL-C and bilirubin can be promising thera-
peutic targets in the treatment of cardiovascular diseases.
Analysis of cell-free  mRNA in plasma might become a use-
ful tool for estimating statin pleiotropy.
Keywords: high-density lipoprotein subclasses, cathep-
sin S, bilirubin, mRNA in plasma, atorvastatin
Rezultati: U grupi A, posle terapije, HDL-C koncentracija se
zna~ajno pove}ala, ali ne i u grupi B. Atorvastatin je snizio
plazmatski nivo hemokin (C-C motiv) liganda 2 i intracelu-
larnog adhezionog molekula-1 mRNA u obe grupe, ali nije
promenio plazmatski nivo gena za katepsin S. Samo u grupi
A, ukupni bilirubin je pokazao negativnu korelaciju sa genom
za katepsin S (r=–0,506; p=0,023) pre zapo~injanja tera -
pije i zna~ajni porast nakon terapije atorvastatinom.
Zaklju~ak: HDL-C i bilirubin mogu biti obe}avaju}i terapijski
ciljevi u le~enju  kardiovaskularnih bolesti. Analiza slobodne
mRNA (eng. cell-free mRNA) u plazmi mo`e postati korisno
sredstvo  za procenu  plejotropnog delovanja statina.
Klju~ne re~i: subfrakcije lipoproteina velike gustine,
katepsin S, bilirubin, mRNA u plazmi, atorvastatin
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Nucleic Acid Kit (Qiagen, Hilden, Germany) accord-
ing to the manufacturer’s instructions, with certain
modifications. The time of proteolysis was 5 min, and
RNA was eluted from the column with 47 mL of
RNase–free water. Collected eluate was used for the
second elution of RNA from the same column. RNA
eluates were incubated in a 65 °C water bath for 5
min and then immediately placed on ice for another
5 min. The eluted mRNA was transcribed to cDNA
with a Super Script VILO cDNA Synthesis Kit
(Invitrogen, Carlsbad, CA, USA). For more efficient
mRNA transcription to cDNA we increased the incu-
bation time from 60 min to 120 min at 42 °C. The
resulting cDNA solution was stored at –80 °C until
further processing.
The primers used for cDNA transcript quan -
tification (TaqMan Gene Expression Assay, Applied
Biosystems, Foster City, CA, USA) were:
Hs00164932_m1 for ICAM1 (exon boundary 2-3,
amplicon length 87 bp), Hs00234140_m1 for CCL2
(exon boundary 1–2, amplicon length 101 bp),
Hs00175403_ml for CTSS (exon boundary 3–4,
amplicon lengh 82 bp) and Hs99999905_ml for
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
as the reference gene.
Four pairs of samples were chosen for selection
of the most appropriate reference gene among the
32 candidates available on the TaqMan Human
Endogenous Control Plate (Applied Biosystems). The
cDNA transcripts were amplified by PCR according to
the manufacturer’s protocol with FastStart Universal
Probe Master (ROX) (Roche Applied Science,
Mannheim, Germany), using 11.25 mL diluted (1:3)
of cDNA (CCL2, ICAM1); 11.25 mL diluted (1:8) of
cDNA (CTSS) and 10.00 mL diluted (1:12) of cDNA
(GAPDH) and the kit components in a total reaction
volume of 25 mL run in an ABI PrismTM SDS PCR
analyser (Applied Biosystems).
The possibility of DNA interference was exclud-
ed by starting PCR reaction with samples of the sub-
ject but omitting the reverse transcription for every
commercially available TaqMan Gene Expression
Assay. Negative control (blank) was analysed to
exclude the possibility of external mRNA contamina-
tion. The coefficient of variation (CV) of Ct was less
than 2% between three averaged Ct values (14). The
amount of each investigated transcript was nor-
malised to the amount of the reference gene (15).
HDL subclasses determination 
Particle size and distribution of HDL subclasses
were assessed by a method of polyacrylamide gradi-
ent gel electrophoresis, introduced by Rainwater et al.
(16). The procedure described in detail has been
published elsewhere (17, 18). Briefly, in house made
polyacrylamide gradient (3–31%) gels were
processed in a Hoefer SE 600 Ruby electrophoresis
unit (Amer sham Pharmacia Biotech, Vienna, Austria)
for 20 h, at 8 °C using Tris (90 mmol/L)–boric acid
(80 mmol/L)–Na2EDTA (2.7 mmol/L) buffer, pH
8.35. For calibration purposes, we used Pharmacia
High Molecular Weight protein standards, carboxylat-
ed polystyrene microsphere beads and standard
samples of human plasma, standardized in Dr. David
Rain water’s Laboratory (Southwest Foundation for
Bio medical Research, San Antonio, TX, USA).
Following electrophoretic separation, the gels were
stained for proteins with Coomassie brilliant blue G-
250 and for lipids with Sudan black. Image Scanner
(Amersham Pharmacia Biotech, Vienna, Austria) with
Image Quant software (version 5.2; 1999; Molecular
Dy namics) was used as a device for densitometric
analysis of the gels. By using the calibration curve cre-
ated of migration distances of standards with known
particle diameters, we calculated particle diameters
corresponding to each absorbance peak in the HDL
regions of gels. Dominant HDL particle diameter was
assessed by estimation of the diameter of the major
absorbance peak. The relative content of each HDL
subclass was evaluated through determination of the
areas under the peaks of densitometric scans. The
relative proportion of small-sized HDL particles was
assessed as the area of the densitometric scan at or
below 8.8 nm (19). Increased small sized HDL parti-
cles were considered if more than 50% of total HDL
absorbance was detected in the area ≤8.8 nm.
Oxidized low-density lipoprotein quantification in
plasma
Oxidized low-density lipoprotein (OxLDL) was
assessed by means of a solid phase dissociation
enhanced lanthanide time-resolved fluorescence
immunoassay (DELFIAR) based on the sandwich
technique (20), using the monoclonal antibody
OB/04 (21), and 24 hours oxidized LDL as a stan-
dard. The plates were precoated with OB04, directed
against an epitope generated on oxidized apolipopro-
tein B (apo B) upon oxidation. The plates were incu-
bated with diluted plasma samples, applied in dupli-
cate at room temperature on a plate shaker. After 2
hours the plates were washed 4 times using a plate
washer (Anthos Fluido Laptec, Salzburg, Austria), to
remove nonreactive plasma components. Then, the
plates were incubated for 1 hour at 4 °C with a rabbit
anti-apo B antibody (Behring, Mannheim, Germany),
which recognized the OxLDL bound to the solid
phase. The second washing step (4 times) removed
unbound anti-apo B antibody. As the last step the
wells were incubated with an Eu-labeled antirabbit
IgG for 1 h at room temperature. The antibody
(Sigma, St. Louis, MO, USA) was labeled with an Eu-
labeling kit (Perkin Elmer, Waltham, MA, USA). The
fluorescence was developed using the enhancement
solution, after washing the plates for 6 times. Eu3+
was dissociated from the labeled antibody by a low
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pH, whereafter the free lanthanide formed a fluores-
cent chelate with the components of the enhance-
ment solution. Counts were measured on a ViktorTM
multilabel counter (Perkin Elmer).
Lipids quantification and protein quantification in
plasma 
HDL-C, LDL-C, TC, triglycerides and total bili -
rubin were measured by reagents from Roche Diag -
nostics (Roche Diagnostics, Mannheim, Germany).
Commercial ELISA kit (Invitrogen, Frederick, MD,
USA) was used for measurement of serum amyloid A
(SAA). C-reactive protein (CRP) was measured by
Beckman Coulter CRP Latex reagent (Beckman
Coulter, Inc. Brea, CA, USA). 
Statistical analysis
Calculations were performed using SPSS v.20.0
(SPSS Inc. Chicago, IL, USA). Numerical data are
shown as median and interquartile range for non-nor-
mally distributed variables. Categorical variables are
presented as relative frequencies. Comparisons of the
data before and after 10 weeks of atorvastatin thera-
py were performed by the Wilcoxon’s signed-rank test
for non-normally distributed variables. The Mann-
Whitney U-test was used to compare data between
subgroups with HDL-C ≤ 1.2 mmol/L and HDL-C >
1.2 mmol/L. Continuous variables are presented as
mean±standard deviation and were compared by the
Student’s t-test. Categorical variables are presented
as relative frequencies and were compared by the
Chi-square test. The Spearman rank-order correlation
test was used for determining relations between the
variables.
Results
Patients were divided in two groups according to
HDL-C. Patients with HDL-C ≤ 1.2 mmol/L (<1.0
mmol/L for men, <1.2 mmol/L for women, n = 20),
also known as high-risk values, were represented by
group A, and patients with borderline and desirable
values, i.e. > 1.2 mmol/L were represented by group
B (n=23). There were no differences between the
two analysed groups (Table I). Group A comprised
three smokers and group B two. Patients were taking
other therapy prior to inclusion into this study (Table
I). Patients took drugs before and continued with the
statins without time between.
Baseline laboratory parameters and their chan -
ges after 10 weeks of atorvastatin treatment are
shown in Table II, Table III and Figure 1. After therapy
there was a significant difference between small-sized
HDL particles and total bilirubin values between the
two groups. Likewise, HDL 2b was different in group
A and group B, at baseline (median 39.28 vs. 43.87,
p=0.054) and after the therapy (median 40.92 vs.
47.13, p=0.013). Figure 1 represents the distribution
of HDL subclasses in both groups of patients. As
shown, atorvastatin treatment significantly increased
HDL 2b in group B only (p=0.004).
There was no correlation between the degree of
changes in the plasma LDL-C after 10 weeks of statin
treatment and the degree of changes in the following
plasma biochemistry markers: CCL2 mRNA, ICAM1
mRNA, CTSS mRNA, CRP and SAA (results not
shown). 
In group A, HDL-C negatively correlated with
small-sized HDL at baseline (r=–0.486; p=0.030)
and positively correlated with dominant particle diam-
eters HDL (r=0.555; p=0.011). As expected, HDL-
C correlated with TG (r=–0.529; p=0.011). In group
Table I Clinical characteristics of the 43 patients with stable angina.
Parameter 
Patients with HDL-C 
≤1.2 mmol/L
n=20 (group A)
Patients with HDL-C 
>1.2 mmol/L
n=23 (group B)
p
Age (years) 60.95±8.62 62.13±9.74 0.678
Body mass index 27.87±6.96 28.40±3.34 0.758
Gender (female) 60.0% 82.6% 0.099
ACE inhibitors 80.0% 60.9% 0.173
Beta blockers 60.0% 34.8% 0.098
Calcium channel blockers 30.0% 34.8% 0.739
Acetylsalicylic acid 15.0% 8.7 % 0.520
Nitrate drugs 45.0% 39.1% 0.697
Continuous variables are presented as mean±standard deviation and were compared by the Student’s t-test, whereas categorical
variables are presented as relative frequencies and were compared by the Chi-square test. Abbreviations: ACE, angiotensin-con-
verting enzyme.
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Table II Lipids before and after atorvastatin treatment in the patients with stable angina.
Table III Laboratory characteristics of stable angina patients at baseline and after 10 weeks of atorvastatin therapy.
Patients with HDL-C ≤ 1.2 mmol/L 
n=20 (group A)
Patients with HDL-C > 1.2 mmol/L
n=23 (group B)
Baseline After 10 weeks p Baseline After 10 weeks p
HDL-C (mmol/L) 1.0(0.9–0.1)§,***
1.2
(1.0–1.3)§,*** 0.002
1.6
(1.4–1.8)
1.5
(1.4–1.8) 0.962
Dominant HDL diameter (nm) 9.26(8.81–9.66)
9.60
(9.10–10.60) 0.014
9.27
(9.04–10.60) 
9.8
(9.50–10.70) 0.051
Small-sized HDL particles (%) 35.56(31.50–42.00)
33.03
(31.22–37.71)§,* 0.279
31.41
(27.93–38.94)
28.80
(23.82–37.84) 0.002
LDL-C (mmol/L) 4.9(4.3–5.6)
2.6
(2.4–3.2) <0.001
4.7
(4.4–5.0)
2.7
(2.4–3.0) <0.001
OxLDL (mg/L) 17.93(14.64–19.96)
11.02
(9.47–12.94) 0.002
15.92
(13.62–17.81)
11.00
(9.75–14.20) 0.003
TC (mmol/L) 7.1(6.6–7.9)
4.3
(4.2–5.0) <0.001
7.1
(6.6–7.4)
4.9
(5.5–5.2) <0.001
TG (mmol/L) 2.2(1.5–3.4)§,**
1.7
(1.30–2.3)§,** 0.005
1.5
(1.1–1.8)
1.2
(1.1–1.6) 0.060
Patients with HDL-C ≤ 1.2 mmol/L 
n=20 (group A)
Patients with HDL-C > 1.2 mmol/L
n=23 (group B)
Baseline After 10 weeks p Baseline After 10 weeks p
CCL2 mRNA 9.50(6.00–11.17)
5.67
(5.00–7.83) 0.028
8.25
(5.67–10.41)
5.86
(4.71–6.92) 0.042
ICAM1 mRNA 63.37(46.36–76.45)
46.92
(34.60–48.66) 0.051
66.34
(35.95–83.36)
39.71
(26.87–48.47) <0.001
CTSS mRNA  29.40(17.40–39.11)
33.76
(26.30–39.38) 0.970
36.51
(26.51–44.48)
29.62
(25.63–34.90) 0.465
Total bilirubin (mmol/L) 6.8(6.4–10.10)
9.4
(7.6–12.4) §,* <0.001
7.0
(5.3–10.3)
6.7
(5.4–9.7) 0.080
CRP (mg/L) 1.9(1.1–3.6)
1.5
(1.0–3.1) 0.332
2.8
(1.7–5.1)
1.9
(1.2–3.7) 0.011
SAA (mg/L) 
22.11
(12–31.25)
15.0
(7.60–18.83) 0.011
23.74
(13.27–33.38)
13.85
(10.53–25.27) 0.004
The values are presented as medians (Q1-Q3) and compared by the Wilcoxon’s test. 
§ Significantly different from patients with HDL-C > 1.2 mmol/L at the same time point, according to Mann-Whitney U test. 
*p<0.05; ** p<0.01; *** p<0.001. 
Abbreviations: HDL-C, high density cholesterol; LDL-C, low-density lipoprotein cholesterol; OxLDL, oxidized low-density lipopro-
tein; TC, total cholesterol; TG, triglycerides; p, level of significance.
The values are presented as medians (Q1-Q3). 
CCL2 mRNA, ICAM1, CTSS mRNA levels were standardised to the mRNA level of glyceraldehyde-3-phosphate dehydrogenase
as a reference gene.
Data are compared by Wilcoxon’s test.  §Significantly different from patients with HDL-C > 1.2 mmol/L at the same time point,
according to Mann-Whitney U test. *p<0.05.
Abbreviations: CCL2, gene encoding monocyte chemoattractant protein-1; CTSS, gene encoding cathepsin S; ICAM1, gene
encoding intercellular adhesion molecule-1; CRP, C-reactive protein; SAA, serum amyloid A; p, level of significance. 
B, HDL-C positively correlated with HDL dominant
particle diameter at baseline (r=0.433; p=0.039)
and, as expected, HDL-C negatively correlated with
TG (r=–0.514; p=0.012). 
In group A only, baseline correlation was
impressive: total bilirubin showed correlation with
CTSS mRNA (r=–0.506; p=0.023). 
Discussion
Atorvastatin (20 mg/day, 10 weeks) was more
effective in patients with high-risk values (group A)
than in the group with borderline and desirable HDL-
C values (group B). In group A, after therapy, HDL-C
was significantly increased but not in group B (Table
II). A drug induced increase of HDL-C levels is asso-
ciated a with mild reduction of CV risk (22). The
antiatherogenic function of HDL relates to their abili-
ty to promote the efflux of cholesterol from cells, so
as to their antiinflammatory and antioxidant proper-
ties (1). However, the atheroprotective function of
HDL is related not only to the plasma concentration
of HDL-C, but also to the distribution and functional
characteristics of HDL particles. It is known that
altered small-sized HDL particles have a diminished
ability to protect LDL from oxidation, a reduced
reverse cholesterol transport capacity and antiinflam-
matory properties (1).
Small-sized HDL particles were more prevalent
in group A than in group B, reaching statistically sig-
nificant difference after therapy (Table II). A relatively
high baseline proportion of small-sized HDL particles
in group A (Table II) could not be significantly re -
duced by atorvastatin, unlike in group B. In this study,
atorvastatin’s beneficent effect on the HDL 2b sub-
classes was present in both groups, but significantly
more so in group B (Figure 1).
Results of some studies indicated that HDL 2b,
which is highly correlated with HDL-C, is strongly
inversely related to CHD risk (23, 24). In our study
there was a difference in HDL 2b between group A
and group B, at baseline and after therapy. HDL 2b
subclasses were more prevalent in group B where the
patients had a more favourable risk profile. In both
groups, the treatment shifted HDL subclasses distri-
bution toward larger particles which is in agreement
with the study by Asztalos et al. (25). In addition, our
finding of significantly increased dominant HDL
diameter after atorvastatin therapy in group A (Table
II) is in line with the studies (26, 27) which showed
beneficial effects of statins through the increase of
large HDL particles that have considerably stronger
antiatherogenic properties. Although the literature is
indicative of HDL-C antioxidative, antiapoptotic and
antiinflammatory activities, in the study there were no
correlations of HDL-C with bilirubin and HDL-C with
genes that are significant for the aforementioned
effects (results not shown). The reason for this may be
the limitations in our study, such as the small number
of samples, the short treatment time of 10 weeks and
the monitoring of pleiotropic effects only once,
after 10 weeks of therapy (a one-time assessment).
This study indicates that atorvastatin in stable
angina patients lowered the plasma mRNA levels of
statin pleiotropy-targeted genes ICAM1 and CCL2 in
both groups. This reduction was obviously independ-
ent from the LDL-C reduction (results not shown).
This paper, and the previous paper (7), shows that
short-term atorvastatin treatment results in anti -
inflammatory effects, presumably by different mecha-
nisms, including the inhibition of nuclear factor kappa
B (NF-kB) (28) and the interference with the prenyla-
tion of small G proteins (such as Rho and Ras) (29).
Current studies suggest that statins increase
CTSS in the plasma, by statin-induced apoptosis of
vascular cells (30). However, this suggestion has lim-
itations because statin treatment did not change the
activity of CTSS in the wall of abdominal aortic
aneurysma in one small case-control study (31) and
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Figure 1 Distributions of HDL subclasses in patients with
HDL-C ≤ 1.2 mmol/L and patients with HDL-C > 1.2
mmol/L. **p<0.01.
Patients with HDL-C ≤ 1.2 mmol/L 
Patients with HDL-C > 1.2 mmol/L 
60.0
Baseline
After 10 weeks50.0
40.0
30.0
20.0
10.0
0.0
**
HDL2b HDL2a HDL3a HDL3b HDL3c
%
60.0
Baseline
After 10 weeks50.0
40.0
30.0
20.0
10.0
0.0
HDL2b HDL2a HDL3a HDL3b HDL3c
%
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CTSS deficiency by itself reduces apoptosis of vascu-
lar macrophages (11). In our study atorvastatin did
not change the plasma CTSS mRNA level in both
groups. An alternative explanation could be that ator-
vastatin in our patients downregulated inflammation
and oxidative stress, which further lowered CTSS
expression, or atorvastatin in our study improved the
balance between CTSS activity and cystatin C (a
potent endogenous CTSS inhibitor), but again, this
suggestion has limitations because we could not
recognise any change in the plasma CTSS mRNA
level. However, it is significant that in the group A
subjects, the plasma total bilirubin concentration was
associated with the baseline plasma CTSS mRNA.
Bilirubin is recognised as a potent antioxidant (32)
and a lower total bilirubin could mean higher oxida-
tive stress. In the development of vascular disease,
oxidative stress plays a critical role. The subjects with
elevated bilirubin levels had diminished risk of ather-
osclerosis (33). The apoptotic cell death is caused by
cellular depletion of bilirubin (34) and consequently
increases CTSS in the plasma. A negative correlation
between bilirubin and CTSS mRNA in our clinical
study (in line with in vitro studies) is significant since
it leads to novel therapy directives aimed at prevent-
ing the clinical progression of atheroma. Bilirubin cor-
relation with CTSS mRNA raises the question as to
whether lower values of bilirubin could be a therapeu-
tic target in the field of atherosclerosis. Some studies
suggest that cathepsin S is involved in the complex
pathways of cardiovascular disease and cancer. The
study by Jobs et al. (35) revealed higher serum
cathepsin S levels in elderly individuals in 2 independ-
ent groups were associated with an increased mortal-
ity risk. It is evident that increased bilirubin will cause
lower expression of the CTSS mRNA, the gene asso-
ciated with a higher mortality risk.
Thus, it is not easy to form an exact image of the
mechanism of negative correlation between bilirubin
and CTSS mRNA in the group A patients, and we
have to propose that more detailed studies are need-
ed to elucidate this issue.
Our study shows that, in stable angina patients,
atorvastatin increased the plasma total bilirubin con-
centrations in group A only. These results (Table III)
are in line with the abovementioned increase of dom-
inant HDL diameter and large HDL 2b subclasses
(Table II). Wallner M et al. (36) showed that elevated
circulating bilirubin is associated with a reduced con-
centration of proatherogenic lipids and inflammation
biomarkers. Statins increase total bilirubin that pro-
tects LDL from oxidation (37), which then reduces
oxidative stress. On the other hand, a more favo u -
rable oxidative status after 10 weeks of therapy (lower
concentration of Ox LDL) could lead to savings of
bilirubin, a potent antioxidant, which is reflected in a
higher concentration of bilirubin in the plasma.
Altogether, our results indicated favourable
effects of statins on two compounds of the antioxida-
tive defence system: bilirubin and large HDL 2b sub-
classes. The fact that elevations of both the concen-
tration of bilirubin and the proportion of HDL 2b were
more prominent in group A, which is more vulnerable
in terms of antiatherogenic protection, is especially
important. These findings suggest that low HDL-C
concentration may also be a target for beneficial
effects of statins. Results from Table III raise the ques-
tion about the necessary length of therapy before
evaluating the antioxidant activity of statins. Likewise,
our results suggest that a significant decrease of SAA
and CRP in plasma is not due to the atorvastatin
effect on LDL cholesterol, but is a consequence of the
pleiotropic effects of atorvastatin. Atorvastatin exerts
a number of pleiotropic effects, which include anti-
inflammatory and antioxidative activities. However,
further, well planned studies are needed to evaluate
our currently observed results.
Conclusions
The results suggest that routine care in stable
angina patients could be complemented with new
therapeutic approaches to raise HDL-C. HDL-C may
become a therapeutic target equal to LDL-C in the
field of CVD and atherosclerosis. The beneficial effect
of atorvastatin on bilirubin also suggests that bilirubin
can be a new therapeutic target in CVD. Analysis of
cell-free mRNA in plasma could be a new tool in non-
invasive assessment of statin pleiotropy.
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